



LKT Laboratories, Inc.

Regorafenib Anhydrous

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information


Product ID R1627
CAS No. 755037-03-7
Chemical Name Regorafenib

Synonym BAY73-4506

Formula $C_{21}H_{15}ClF_4N_4O_3$
Formula Wt. 482.82
Melting Point
Purity $\geq 99\%$
Solubility

Store Temp $-20^{\circ}C$
Ship Temp Ambient

Description Regorafenib is an orally bioavailable multikinase inhibitor. This compound is clinically used in the treatment of metastatic colorectal cancer and non-responsive gastrointestinal stromal tumors. Regorafenib displays anticancer chemotherapeutic and anti-angiogenic properties, selective primarily for VEGFR2 but also displaying inhibitory activity against TIE2, VEGFR1/3, PDGFR- β , FGFR1, c-Kit, RET, and B-Raf. TEST!!!!!!



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
R1627	1 mg	\$35.00
R1627	5 mg	\$45.00
R1627	25 mg	\$75.00
R1627	100 mg	\$190.00

References Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. *Mol Cancer Ther.* 2013 Jul;12(7):1322-31. PMID: 23619301.

Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. *Int J Cancer.* 2011 Jul 1;129(1):245-55. PMID: 21170960.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.